Stefani Wolff
Geen lopende functies
Vermogen: 89 861 $ op 31-03-2024
Profiel
Stefani A.
Wolff worked as a Product Manager at Eli Lilly & Co. from 1989 to 1997.
She then worked as a Senior Director at Genentech, Inc. from 2007 to 2010.
In 2013, she became the Vice President-Development at Onyx Pharmaceuticals, Inc. and later served as the Chief Development Officer at Principia Biopharma, Inc. from 2018 to 2020.
In 2021, she became an Independent Director at Rain Oncology, Inc. and the Chief Operating Officer & EVP-Product Development at Nurix Therapeutics, Inc. She also worked as a Principal at BioPharma Consulting Services LLC in 2016-2017.
Wolff received her undergraduate degree from The University of North Carolina at Charlotte in 1989.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
NURIX THERAPEUTICS, INC.
0.01% | 01-05-2023 | 6 113 ( 0.01% ) | 89 861 $ | 31-03-2024 |
Eerdere bekende functies van Stefani Wolff
| Bedrijven | Functie | Einde |
|---|---|---|
| RAIN ONCOLOGY INC. | Director/Board Member | 25-01-2024 |
| NURIX THERAPEUTICS, INC. | Chief Operating Officer | 02-05-2023 |
| PRINCIPIA BIOPHARMA INC. | Corporate Officer/Principal | 28-09-2020 |
| BioPharma Consulting Services LLC | Corporate Officer/Principal | 01-01-2017 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Corporate Officer/Principal | 01-12-2015 |
Opleiding van Stefani Wolff
| The University of North Carolina at Charlotte | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| NURIX THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Principia Biopharma, Inc.
 Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. | Health Technology |
| BioPharma Consulting Services LLC | |
Rain Oncology, Inc.
 Rain Oncology, Inc. BiotechnologyHealth Technology Rain Oncology, Inc. is a clinical-stage precision oncology company, which focuses on developing and implement the precision oncology therapies for patients suffering from cancer. The company was founded by Avanish Vellanki and Robert Doebele in April 2017 and is headquartered in Newark, CA. | Health Technology |
